JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 42, 2014, Pages 15190-15195

  Chen, Edwin ^a,b   Sook Ahn, Jong ^a,b   Massie, Charlie E ^a,b   Clynes, David ^c   Godfrey, Anna L ^a,b,d   Li, Juan ^a,b   Park, Hyun Jung ^a,b   Nangalia, Jyoti ^a,b,d   Silber, Yvonne ^a,b   Mullally, Ann ^e   Gibbons, Richard J ^c   Green, Anthony R ^a,b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

JAK2V617F; Myeloproliferative neoplasm; Replication stress

Indexed keywords

CHECKPOINT KINASE 1; JANUS KINASE 2; JANUS KINASE 2 NON RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIPLOIDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA REPLICATION ORIGIN; ENZYME PHOSPHORYLATION; ERYTHROBLAST; HUMAN; HUMAN CELL; POLYCYTHEMIA VERA; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL CYCLE S PHASE; CELL DIVISION; CHROMOSOME; FIBROBLAST; FLUORESCENCE MICROSCOPY; GENETICS; GENOTYPE; HEMATOLOGIC DISEASE; LEUKEMIA; METABOLISM; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; ULTRASTRUCTURE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIVISION; CHROMOSOMES; DIPLOIDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; FIBROBLASTS; GENOTYPE; HEMATOLOGIC DISEASES; HUMANS; JANUS KINASE 2; LEUKEMIA; MICROSCOPY, FLUORESCENCE; MYELOPROLIFERATIVE DISORDERS; PHOSPHORYLATION; RNA, SMALL INTERFERING; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908072114     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401873111     Document Type: Article

References (39)

1. Jan M, Majeti R (2013) Clonal evolution of acute leukemia genomes. Oncogene 32(2):135-140.
2. Yates LR, Campbell PJ (2012) Evolution of the cancer genome. Nat Rev Genet 13(11):795-806.
3. Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355(23):2452-2466.
4. Kleppe M, Levine RL (2012) New pieces of a puzzle: The current biological picture of MPN. Biochim Biophys Acta 1826(2):415-422.
5. Baxter EJ, et al.; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054-1061.
6. James C, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144-1148.
7. Kralovics R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779-1790.
8. Levine RL, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387-397.
9. Zhao R, et al. (2008) Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 359(26):2778-2789.
10. Marty C, et al. (2013) A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 27(11):2187-2195.
11. Li J, et al. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 116(9):1528-1538.
12. Plo I, et al. (2008) JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders. Blood 112(4):1402-1412.
13. Fernandes MS, et al. (2009) BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 114(9):1813-1819.
14. Bester AC, et al. (2011) Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145(3):435-446.
15. Cobb JA, et al. (2005) Replisome instability, fork collapse, and gross chromosomal rearrangements arise synergistically from Mec1 kinase and RecQ helicase mutations. Genes Dev 19(24):3055-3069.
16. Lambert S, Watson A, Sheedy DM, Martin B, Carr AM (2005) Gross chromosomal rearrangements and elevated recombination at an inducible site-specific replication fork barrier. Cell 121(5):689-702.
17. Cortes-Ledesma F, Aguilera A (2006) Double-strand breaks arising by replication through a nick are repaired by cohesin-dependent sister-chromatid exchange. EMBO Rep 7(9):919-926.
18. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220-228.
19. Conti C, et al. (2007) Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell 18(8):3059-3067.
20. Chen E, et al. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18(5):524-535.
21. Komarov PG, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285(5434):1733-1737.
22. Beer PA, et al. (2009) Clonal diversity in the myeloproliferative neoplasms: Independent origins of genetically distinct clones. Br J Haematol 144(6):904-908.
23. Schaub FX, et al. (2009) Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 113(9):2022-2027.
24. Gorgoulis VG, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035):907-913.
25. Bartkova J, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864-870.
26. Di Micco R, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119):638-642.
27. Weinberger M, et al. (2010) Growth signaling promotes chronological aging in budding yeast by inducing superoxide anions that inhibit quiescence. Aging (Albany, NY Online) 2(10):709-726.
28. Cha TL, et al. (2005) Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310(5746):306-310.
29. Huang WC, Chen CC (2005) Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25(15):6592-6602.
30. Estève PO, et al. (2011) A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability. Nat Struct Mol Biol 18(1):42-48.
31. Nangalia J, et al. (2013) Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med 369(25):2391-405.
32. Huang Z, et al. (2007) STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest 117(12):3890-3899.
33. Olthof SG, et al. (2008) Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis. Stem Cells 26(7):1732-1742.
34. Godfrey AL, et al. (2012) JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood 120(13):2704-2707.
35. Klampfl T, et al. (2011) Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118(1):167-176.
36. Harutyunyan A, Klampfl T, Cazzola M, Kralovics R (2011) p53 lesions in leukemic transformation. N Engl J Med 364(5):488-490.
37. Mesa RA, et al. (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 105(3):973-977.
38. Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14(4):397-402.
39. Thoennissen NH, et al. (2010) Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115(14):2882-2890.